Given the exciting results from DESTINY-Lung01, a randomized, open-label, phase 3 trial (DESTINY-Lung04; NCT05048797) is underway to further evaluate the efficacy and safety of T-Dxd compared to standard of care (pembrolizumab combined with chemotherapy) in non-squamous NSCLC patients harboring a HER2 exon 19 or 20 mutations. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.